Eosinophilic Chronic Obstructive Pulmonary Disease: Implications for Exacerbations, Readmissions, and Treatment

Vashi, Mona; Willoughby, J.; Quinn, Steven; Tran, Betty T.

doi:10.1164/rccm.201802-0328rr

Cited by 6 publications

(3 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is also known that the BEC is not stable in the long term, as demonstrated in longitudinal studies performing repeated determinations of these counts, in which it was observed that, although most patients had persistently high or low levels, a group of them could be classified on some occasions in the elevated BEC group, and on others in the low BEC group …”

Section: Discussionmentioning

confidence: 99%

“…22 It is also known that the BEC is not stable in the long term, as demonstrated in longitudinal studies performing repeated determinations of these counts, in which it was observed that, although most patients had persistently high or low levels, a group of them could be classified on some occasions in the elevated BEC group, and on others in the low BEC group. 12,25,[35][36][37] The fact that patients with higher BEC have a higher risk of late readmissions should be considered in order to decide on both their treatment at discharge and the scheduled follow-up after their discharge.…”

Section: Ta B L E 1 (Continued)mentioning

confidence: 99%

See 1 more Smart Citation

Blood eosinophils could be useful as a biomarker in chronic obstructive pulmonary disease exacerbations

Barcala

San-Jose²,

Nieto‐Fontarigo

et al. 2019

Int J Clin Pract

View full text Add to dashboard Cite

Summary IntroductionThe aim of analysing the usefulness of the blood eosinophil count (BEC) as a prognostic marker in exacerbations of patients with Chronic Obstructive Pulmonary Disease (COPD), evaluating its relationship with hospital mortality, the length of stay and the early and late re‐admissions. Materials and MethodsWe have carried out a retrospective study including all patients who required hospital admission from 1 January 2008 to 31 December 2009, with a diagnosis on hospital discharge of COPD exacerbation. These patients were classified using three cut‐off points of BEC: less than 200 vs ≥ 200/µL, less than 300 vs ≥ 300/µL and less than 400 vs ≥ 400/µL. ResultsThere were a total of 1626 hospital admissions during the study period with the diagnosis of exacerbation of COPD. In this study we have included 358 patients. The probability of any late re‐admission increased with a BEC ≥ 300/µL (odds ratio: 1.684) and for those with a BEC ≥ 400/µL (odds ratio: 2.068). The BEC does not appear to be related to hospital mortality or the probability of early re‐admission after an exacerbation of COPD. ConclusionsIn our study an elevated BEC is associated with a higher incidence of late hospital readmissions in COPD exacerbations.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Ta B L E 1 (Continued)mentioning

confidence: 99%

Blood eosinophils could be useful as a biomarker in chronic obstructive pulmonary disease exacerbations

Barcala

San-Jose²,

Nieto‐Fontarigo

et al. 2019

Int J Clin Pract

View full text Add to dashboard Cite

show abstract

“…20 This was characterized by sputum eosinophils > 3% or blood eosinophils ≥ 2%. 21 The increased blood eosinophils in COPD had a one-way relationship with sputum eosinophils. In COPD exacerbations, the percentage of peripheral blood eosinophils ≥ 2% can be used as a sensitive biomarker to determine sputum eosinophils > 3%.…”

Section: Percentage Of Blood Eosinophils Of the Study Subjectsmentioning

confidence: 98%

Correlation between FEV1% Predicted and Blood Eosinophils in Patients with Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)

Nurfaizi

Marhana

Sari

et al. 2021

View full text Add to dashboard Cite

Introduction: Chronic obstructive pulmonary disease (COPD) exacerbations are still the leading causes of mortality. Eosinophil counts were recommended in assessing the risk of exacerbations. This additional examination was preferred rather than the pulmonary function test (PFT), which was considered less precise and had vast differences. Therefore, an analysis of the correlation between the FEV1% predicted and blood eosinophil counts were needed as a reference in the diagnosis of COPD exacerbation. This study aimed to determine the correlation between FEV1% predicted and blood eosinophils counts in patients with COPD exacerbations.Methods: This was a retrospective cross-sectional study by analyzing medical records of patients with COPD exacerbations at Dr. Soetomo General Hospital, Surabaya, from 2017 to 2018.Results: The characteristics of patients with exacerbations of COPD consisted of 91.7% male patients. Most of them were in the age group of 61-70 years old, 58.3% were in the private sector, 75% had a high school diploma, and 41.7% had normal body mass index (BMI). The percentage of the FEV1% predicted is directly proportional to the percentage of blood eosinophils with weak and statistically insignificant strength.Conclusion: The FEV1% predicted and blood eosinophil counts had a very weak correlation and statistically insignificant strength. Thus, it could not be used as a reference for diagnosis using one of the variables. Further research is needed with sputum eosinophils and biopsy as consideration for more accurate results.

show abstract

Management of screen-detected lung nodules: A Canadian partnership against cancer guidance document

Lam

Bryant

Donahoe

et al. 2020

Canadian Journal of Respiratory, Critical Care, and Sleep Medic

View full text Add to dashboard Cite

show abstract

Eosinophilic Chronic Obstructive Pulmonary Disease: Implications for Exacerbations, Readmissions, and Treatment

Cited by 6 publications

References 4 publications

Blood eosinophils could be useful as a biomarker in chronic obstructive pulmonary disease exacerbations

Blood eosinophils could be useful as a biomarker in chronic obstructive pulmonary disease exacerbations

Correlation between FEV1% Predicted and Blood Eosinophils in Patients with Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)

Management of screen-detected lung nodules: A Canadian partnership against cancer guidance document

Contact Info

Product

Resources

About